ES2060045T3 - Procedimiento para reducir el tamaño del cristal del dihidrato de hidrocloruro de ondansetron. - Google Patents

Procedimiento para reducir el tamaño del cristal del dihidrato de hidrocloruro de ondansetron.

Info

Publication number
ES2060045T3
ES2060045T3 ES90307044T ES90307044T ES2060045T3 ES 2060045 T3 ES2060045 T3 ES 2060045T3 ES 90307044 T ES90307044 T ES 90307044T ES 90307044 T ES90307044 T ES 90307044T ES 2060045 T3 ES2060045 T3 ES 2060045T3
Authority
ES
Spain
Prior art keywords
reduce
hydrochloride dihydrate
crystal size
procedure
ondansetron hydrochloride
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES90307044T
Other languages
English (en)
Inventor
David Trevor Collin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10659180&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2060045(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Application granted granted Critical
Publication of ES2060045T3 publication Critical patent/ES2060045T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hospice & Palliative Care (AREA)
  • Animal Behavior & Ethology (AREA)
  • Otolaryngology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Iron Core Of Rotating Electric Machines (AREA)
  • Glass Compositions (AREA)

Abstract

LA INVENCION ES RELATIVA A UN PROCESO PARA REDUCIR EL TAMAÑO DE CRISTAL DE CIERTO HIDROCLORURO DIHIDRATO PRODUCIDO POR CRISTALIZACION DE UN DISOLVENTE A UN TAMAÑO EL CUAL ES ADECUADO PARA DISTRIBUCION EFECTIVA EN UNA TABLETA DE MEZCLA, EN PARTICULAR MENOR DE 250(MU)M EN UN 100%. EL HIDROCLORURO DIHIDRATO SE DISUELVE PARA SECARLO A ELEVADA TEMPERATURA Y REDUCIDA PRESION ATMOSFERICA Y ENTONCES SE REHIDRATA
ES90307044T 1989-06-28 1990-06-27 Procedimiento para reducir el tamaño del cristal del dihidrato de hidrocloruro de ondansetron. Expired - Lifetime ES2060045T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB898914804A GB8914804D0 (en) 1989-06-28 1989-06-28 Process

Publications (1)

Publication Number Publication Date
ES2060045T3 true ES2060045T3 (es) 1994-11-16

Family

ID=10659180

Family Applications (1)

Application Number Title Priority Date Filing Date
ES90307044T Expired - Lifetime ES2060045T3 (es) 1989-06-28 1990-06-27 Procedimiento para reducir el tamaño del cristal del dihidrato de hidrocloruro de ondansetron.

Country Status (20)

Country Link
US (1) US5622720A (es)
EP (1) EP0415522B1 (es)
JP (1) JP3093242B2 (es)
KR (1) KR0182789B1 (es)
AT (1) ATE110380T1 (es)
AU (1) AU637110B2 (es)
CA (1) CA2019944C (es)
DE (1) DE69011786T2 (es)
DK (1) DK0415522T3 (es)
ES (1) ES2060045T3 (es)
GB (1) GB8914804D0 (es)
HK (1) HK44495A (es)
HU (1) HU208009B (es)
IE (1) IE64715B1 (es)
IL (1) IL94888A (es)
NZ (1) NZ234267A (es)
RU (1) RU2002745C1 (es)
SA (1) SA90110025B1 (es)
UA (1) UA18249A (es)
ZA (1) ZA905002B (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9310756D0 (en) * 1993-05-25 1993-07-14 Glaxo Lab Sa Compositions
GB9423511D0 (en) * 1994-11-22 1995-01-11 Glaxo Wellcome Inc Compositions
RU2162695C1 (ru) * 2000-07-14 2001-02-10 ООО с иностранными инвестициями "Редди-Биомед лимитед" Способ получения ондансетрона гидрохлорида дигидрата, субстанция и фармацевтический препарат
US20020115707A1 (en) * 2001-01-11 2002-08-22 Rami Lidor-Hadas Process for preparing pure ondansetron hydrochloride dihydrate
RU2185825C1 (ru) * 2001-03-12 2002-07-27 Государственный научный центр - Институт биофизики Фармацевтическая композиция, содержащая ондансетрон и метацин
MXPA04007995A (es) * 2002-02-19 2004-11-26 Teva Pharma Desolvatacion de solvatos de hemicalcio de atorvastatina.
US6717015B2 (en) 2002-03-28 2004-04-06 Synthon Bv Venlafaxine besylate
MXPA04010846A (es) * 2002-04-29 2005-01-25 Biogal Gyogyszergyar Proceso para preparar 1, 2, 3, 9-tetrahidro -9- metil-3 -[(2-metil -1h-imidazol -1-il) metil]- 4h- carbazol -4- ona.
US20050131045A1 (en) * 2002-04-30 2005-06-16 Judith Aronhime Novel crystal forms of ondansetron, processes for their preparation, pharmaceutical, compositions containing the novel forms and methods for treating nausea using them
US20060083759A1 (en) * 2002-07-17 2006-04-20 Aleksander Resman Stabilization of the profile of release of active substances from a formulation
JP5690461B2 (ja) * 2002-11-15 2015-03-25 ヘルシン ヘルスケア ソシエテ アノニム 化学療法誘導嘔吐を治療するためのパロノセトロン
JO2735B1 (en) 2003-01-30 2013-09-15 هيلسين هيلث كير أس ايه. Liquid pharmaceutical formulations of palonosetron
US8598219B2 (en) 2003-01-30 2013-12-03 Helsinn Healthcare Sa Liquid pharmaceutical formulations of palonosetron
TWI355936B (en) * 2003-02-18 2012-01-11 Helsinn Healthcare Sa Uses of palonosetron hydrochloride
US7390503B1 (en) 2003-08-22 2008-06-24 Barr Laboratories, Inc. Ondansetron orally disintegrating tablets
US20060167072A1 (en) * 2004-01-30 2006-07-27 Helsinn Healthcare Sa Liquid pharmaceutical formulations of palonosetron
US7288660B2 (en) 2004-05-07 2007-10-30 Taro Pharmaceutical Industries Limited Process for preparing ondansetron hydrochloride dihydrate having a defined particle size
CA2901244A1 (en) * 2005-02-23 2006-08-31 Teva Pharmaceutical Industries, Ltd. Rasagiline formulations of improved content uniformity
CN101123946B (zh) * 2005-02-23 2013-06-26 泰华制药工业有限公司 改良含量均匀度的雷沙吉兰制剂
EP2007369A4 (en) 2006-04-03 2009-07-01 Teva Pharma USE OF RASAGILINE FOR THE TREATMENT OF LEG SYNDROME WITHOUT REST
CA2666512C (en) * 2006-10-24 2014-05-27 Helsinn Healthcare S.A. Soft capsules comprising palonosetron hydrochloride having improved stability and bioavailability

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU193592B (en) * 1984-01-25 1987-11-30 Glaxo Group Ltd Process for producing tetrahydro-carbazolone derivatives
US4695578A (en) * 1984-01-25 1987-09-22 Glaxo Group Limited 1,2,3,9-tetrahydro-3-imidazol-1-ylmethyl-4H-carbazol-4-ones, composition containing them, and method of using them to treat neuronal 5HT function disturbances
JP2608078B2 (ja) * 1986-12-17 1997-05-07 グラクソ、グループ、リミテッド 医 薬
DK185489A (da) * 1988-04-22 1989-10-23 Duphar Int Res Imidazolylmethyl-cycloalkanoebaaindoloner, deres fremstilling og anvendelse
US5344658A (en) * 1989-06-28 1994-09-06 Glaxo Group Limited Process and composition using ondansetron

Also Published As

Publication number Publication date
HK44495A (en) 1995-03-31
HU208009B (en) 1993-07-28
IE902333A1 (en) 1991-01-16
EP0415522A1 (en) 1991-03-06
UA18249A (uk) 1997-12-25
RU2002745C1 (ru) 1993-11-15
DE69011786T2 (de) 1994-12-15
CA2019944C (en) 2000-05-09
DK0415522T3 (da) 1994-09-19
KR0182789B1 (ko) 1999-10-15
US5622720A (en) 1997-04-22
CA2019944A1 (en) 1990-12-28
EP0415522B1 (en) 1994-08-24
KR910000709A (ko) 1991-01-30
AU5787490A (en) 1991-01-03
HUT54140A (en) 1991-01-28
NZ234267A (en) 1992-11-25
AU637110B2 (en) 1993-05-20
ATE110380T1 (de) 1994-09-15
IE902333L (en) 1990-12-28
JPH0395178A (ja) 1991-04-19
HU904015D0 (en) 1990-12-28
IL94888A (en) 1995-03-15
JP3093242B2 (ja) 2000-10-03
GB8914804D0 (en) 1989-08-16
SA90110025B1 (ar) 2001-03-24
ZA905002B (en) 1991-12-24
IL94888A0 (en) 1991-04-15
DE69011786D1 (de) 1994-09-29
IE64715B1 (en) 1995-08-23

Similar Documents

Publication Publication Date Title
ES2113881T3 (es) Derivados y analogos de acido 2-desoxi-2,3-didehidro-n-acetil neuraminico y su utilizacion como agentes antivirales.
ES2047342T3 (es) Productos autoestables de arroz y procedimientos para su produccion.
ES2174992T3 (es) Productos intermediarios para la obtencion de compuestos inhibidores de proteasas retrovirales.
DK0415522T3 (da) Fremgangsmåde til reducering af krystalstørrelsen af ondansetron-hydrochlorid-dihydrat
ES454964A1 (es) Un procedimiento para la preparacion de acido 7-d-(-)-alfa- amino-alfa-(p-hidroxifenilacetamido) desacetoxicefalospora- nico, hidrato o sales farmaceuticamente aceptables del mis- mo.
ES2113682T3 (es) Procedimiento y dispositivo para la limpieza de elementos solidos.
ES2045009T3 (es) El acido taurohyodesoxicolico para la terapia de calculosis del tracto biliar y de la dispepsia biliar.
ES461415A2 (es) Procedimiento para la preparacion de vacunas acelulares.
AR010938A1 (es) Procedimiento para preparar acido l-ascorbico.
NO872671L (no) 4-benzyloksy-3-pyrrolin-2-on-1-yl-acetamid, fremstilling og anvendelse derav.
ES8404373A1 (es) Un procedimiento para obtener compuestos de ribofuranosilselenazol-4-carboxamida.
ES2151891T3 (es) Derivados de ciclohexano sustituidos con imidazolilo.
DK106277C (da) Fremgangsmåde til fremstilling af cyclododecatrien-(1,5,9) og højere oligomere ud fra 1,3-diener.
ES2191035T3 (es) Derivados de la pirona como inhibidores de la proteasa y agentes antiviricos.
CH418527A (fr) Procédé de préparation de la vitamine B12
CH304028A (fr) Procédé de fabrication de chlorate de sodium par voie électrolytique.
CO4230099A1 (es) Procedimiento para preparar b-lactama cristalina monohidrato
ES2042571T3 (es) N-(s-3-metilftanoil)-d-gamma-glutamil-glicil-d-alanina cristalina, y procedimientos y productos intermedios de la misma.
MX9401456A (es) Derivados novedosos del acido 3-hidroxiantranilico, proceso para su preparcion y formulaciones farmaceuticas que los incluyen.
IT1064766B (it) Processo per la preparazione di aih3(po4)2,3h2o
JPS5253878A (en) Process for preparing 2-alkoxy-3h-azepines
IT7920146A0 (it) Procedimento per la preparazione di derivati del tiazolo, particolarmente utili come medicamenti.
ES472270A1 (es) Un procedimiento para la produccion de derivados 4-n-susti- tuidos de fortimicina b
ES178468A2 (es) Mejoras en la principal
GB811874A (en) Improvements in and relating to the bio-synthesis of vitamins

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 415522

Country of ref document: ES